TCRR News and Press, TCR2 Therapeutics Inc. From 07/25/19

Gainers : Anika Therapeutics (NASDAQ: ANIK ) +34% . TCR2 Therapeutics (NASDAQ: TCRR ) +30% . Diebold Nixdorf (NYSE: DBD ) +26% . EDAP TMS (NASDAQ: EDAP ) +20% . Hovnanian (NYSE: HOV ) +18%.  NETGEAR (NASDAQ: NTGR ) +16% . Meritage Homes (NYSE: MTH ) +16% . Empire Resorts (NASDA...

CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will be added to the Russell 2000®, 3...

The following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this Read more ...

Allogene Therapeutics (NASDAQ: ALLO ) initiated with Neutral rating at Guggenheim. More news on: Allogene Therapeutics, Inc., Fate Therapeutics, Inc., Rubius Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

TCR2 Therapeutics Inc. (TCRR) Q1 2019 Earnings Conference Call May 13, 2019 5:30 PM ET Company Participants Carl Mauch – Director-Investor Relations and Corporate Communications Garry Menzel – Chief Executive Officer Alfonso Quintás – Chief Medical Offic...

TCR2 Therapeutics (NASDAQ: TCRR ): Q1 EPS of -$4.85 may not be comparable to consensus of -$0.53. More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Initiated Phase 1/2 clinical trial for TC-210, TCR 2 ’s lead product candidate targeting mesothelin expressing solid tumors On track to file an IND for TCR 2 ’s lead hematology product candidate, TC-110, in patients with CD19+ non-Hodgkin lymphomas and leukemias in 2H 2019 ...

Preclinical study results published in Nature Communications show superior anti-tumor activity of T cell receptor fusion construct T cells (TRuC™)-T cells compared to chimeric antigen receptor (CAR)-T cells in several mouse models Enhanced in vivo activity of TRuC-T cells over CA...

Earnings to be released after market close on Monday, May 13, 2019 CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (TCR 2 ) (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients sufferi...

Gainers:  Quorum Health (NYSE: QHC ) +38% . Speedway Motorsports (NYSE: TRK ) +33% . Entegra Financial (NASDAQ: ENFC ) +25% . Midatech Pharma (NASDAQ: MTP ) +24% . Appliance Recycling Centers of America (NASDAQ: ARCI ) +23% . Nordic American Offshore (NYSE: NAO ) +23% . Synalloy...